Risk factors and outcome in ambulatory assault victims presenting to the acute emergency department setting: implications for secondary prevention studies in PTSD

Prevention of post-traumatic stress disorder (PTSD) in trauma victims is an important public health goal. Planning for the studies required to validate prevention strategies requires identification of subjects at high risk and recruitment of unbiased samples that represent the larger high-risk population (difficult because of the avoidance of many trauma victims). This study recruited high-risk victims of interpersonal violence (sexual or physical assault) presenting to an urban emergency department for prospective 1- and 3-month follow-up. Of 546 victims who were approached about participating, only 56 agreed to be contacted and only 46 participated in either the 1- or 3-month interviews. Of the 46, 43 had been previously victimized with a mean of over six traumas in the group; 21% had prior PTSD, 85% had prior psychiatric illness, and 37% had prior substance abuse. Sixty-seven percent had positive urine for alcohol or drugs on presentation. Fifty-six percent developed PTSD at 1 or 3 months with the rate declining between 1 and 3 months. There was high use of medical and psychiatric services. These findings document both the difficulty of recruiting large samples of high-risk assault victims to participate in research, and the high rate of prior traumatization, PTSD, substance use, and psychiatric morbidity in these subjects which, if still active at the time of victimization, may complicate efforts to document preventive treatment effects.     

Cocaine and alcohol use preceding suicide in African American and white adolescents

The goal of this investigation was to determine whether cocaine and ethanol use was a differentiating factor between African American and white teenage suicide victims. This is a retrospective analysis of medical examiner's records of all completed suicides in Fulton County, GA from 01/1989 to 12/2003, and included 1296 cases. There were 79 suicide victims aged 19 and younger during the study interval, and of this group, 49 (62%) were African American, 26 (33%) were white, and 4 (5%) other race, compared to adults (20 years) where 28.5% were African American, 68.6% white and 2.9% other race (chi(2)=42.678, d.f.=2, p<0.0001). Of the black teenaged victims, 82.2% had no cocaine or alcohol detected at autopsy, while 41.7% of the white victims were positive for one or both substance (chi(2)=4.633, d.f.=1, p=0.04). Only 8.9% of the black teenage suicide victims had used cocaine prior to death compared to 28% of the whites (chi(2)=4.432; d.f.=1; p<0.04). The suicide rate (suicide/100,000/year) for black teens was 5.48 compared to 4.16 for whites, but the rate of cocaine positive teen suicides was 1.12 for whites and 0.45 for blacks. The pattern of cocaine use changes dramatically in the adult group, with 27% of African American suicide victims compared to 7.7% of whites being positive (chi(2)=73.272; d.f.=1; p<0.001). Use of intoxicating substances does differentiate teenage suicide victims, as only a small proportion of black teenagers had used cocaine or alcohol prior to death compared to almost half of all whites.     

Alcohol consumption and regular benzodiazepine use in 55-year-old female Malmö residents: results of a health screening

The main objective of the present study was to examine the relationship between regular benzodiazepine (BZD) use and drinking patterns in 55-year-old female residents of Malmö, Sweden. All women born in 1935 (a total of 1223 subjects) were invited to a health screening at the Preventive Medicine Section, Malmö General Hospital; 69% agreed to participate. The screening included an extensive health questionnaire, and the responses to 33 items assessing social background, including immigrant status, use of BZD and analgesics, alcohol consumption (the revised Malmö-MAST), smoking and morbidity were analysed. A psychiatric symptoms scale including five of these items was constructed, yielding a Cronbach's alpha of 0.57. Present use of BZD hypnotics and/or tranquillizers was acknowledged by 6% of the women. BZD use at any time in the past or present was endorsed by 23%. Endorsement of ≥3 revised Malmö-MAST items, indicating problem drinking, occurred in 3% of the participants; 16% were teetotallers and about 25% were regular weekend drinkers. BZD use was significantly more likely to occur in women with the following characteristics: early retirement, pain symptoms, longstanding use of analgesics, multiple psychiatric symptoms. Drinking patterns in relation to BZD use indicated that regular weekend drinkers were significantly less likely to be current and/or previous BZD users than problem drinkers and teetotallers. Logistic regression analyses indicated that use of BZDs was mainly predicted by endorsement of multiple psychiatric symptoms.     

Congenital malformations and maternal consumption of benzodiazepines: a case-control study

This study assessed potential teratogenic properties of benzodiazepine (BZD) intake during early pregnancy. Four neonatal diagnoses of congenital malformations (embryopathy and fetopathy, unspecified; unspecified congenital malformations of the nervous system; cleft palate and cleft lip; congenital malformations of the urinary tract) were selected. The authors' previous clinical experience had shown these diagnoses to be characteristic of infants born to mothers with excessive intake of BZD in early pregnancy. The selected diagnoses were present in 25 of 10,646 liveborn infants (2.3 per 1000) delivered by mothers living in the city of Gothenburg in 1985 and 1986. In 18 of these cases, it was possible to analyse maternal plasma, and eight samples (44 per cent) were found to be BZD-positive. Of 60 controls, two maternal blood samples (3 per cent) were positive for BZD. The difference is highly significant and suggests an association between these congenital malformations and BZD consumed during early gestation.     

Multifocal cognitive dysfunction in high-dose benzodiazepine users: a cross-sectional study

Benzodiazepines (BZDs) are the most widely prescribed drug class in developed countries, but they have high potential for tolerance, dependence and abuse. Cognitive deficits in long-term BZD users have long been known, but previous results might have been biased by patients’ old age, coexisting neurological or psychiatric conditions or concurrent alcohol or psychotropic drug dependence. The study was aimed to explore the neuropsychological effect of high-dose BZD dependence, which represents an emerging addiction phenomenon. We recruited a group of high-dose BZD users with neither neurological or psychiatric comorbidity except anxiety or depression nor concurrent alcohol or psychotropic drug dependence. They underwent a battery of cognitive tests to explore verbal, visuospatial memory, working memory, attention, and executive functions. All the neuropsychological measures were significantly worse in patients than controls, and some of them were influenced by the BZD cumulative dose. The severity of depression and anxiety had a minimal influence on cognitive tests. Patients with high-dose BZD intake show profound changes in cognitive function. The impact of cognition should be considered in this population of patients, who may be involved in risky activities or have high work responsibilities.     

Determination of the main risk factors for benzodiazepine dependence using a multivariate and multidimensional approach

The aim of this study was to identify risk factors for benzodiazepine (BZD) dependence, such as sociodemographic variables, characteristics of BZD use, and psychiatric parameters, which to date have been found to relate inconsistently to indicators of BZD dependence such as chronic BZD use and BZD withdrawal symptoms. The Benzodiazepine Dependence Self-Report Questionnaire (Bendep-SRQ), Schedules for Clinical Assessment in Neuropsychiatry (SCAN), and Symptom Checklist-90 (SCL-90) were administered to 599 outpatients using BZDs. Regression analyses were conducted using BZD dependence diagnoses and severity scales as dependent variables. BZD dependence diagnoses were only predicted by being a self-help patient and long BZD elimination half-life (for only the DSM-III-R). The main predictors of BZD dependence severity, as measured by the ICD-10, DSM-III-R scales, and Bendep-SRQ Rasch scales, were in decreasing order: (1) being a self-help patient; (2) higher BZD dose, longer duration of BZD use, younger age; and (3) non-native cultural origin, lower level of education, being in outpatient treatment for alcohol and/or drug dependence, and the interaction of BZD dose with duration of BZD use. We conclude that a limited number of recognizable risk factors appear to predict the severity of BZD dependence. Additional administration of a specific BZD dependence instrument is recommended to confirm suspected BZD dependence and guide further clinical decision-making.     

Acute stress response and posttraumatic stress disorder in traffic accident victims: a one-year prospective, follow-up study

OBJECTIVE: This study was designed to assess the natural course of posttraumatic symptoms formation, as well as the degree to which acute stress reactions predict later posttraumatic stress disorder (PTSD) in injured traffic accident victims. METHOD: A prospective, 1-year follow-up study was carried out on 74 injured traffic accident victims and a comparison group of 19 patients who were hospitalized for elective orthopedic surgery. Participants were interviewed within the first week following the accident, and follow-up interviews were performed 1, 3, 6, and 12 months after the accident. At 12 months, a structured clinical interview was administered to determine a formal DSM-III-R diagnosis of PTSD. RESULTS: Twenty-four (32%) of the 74 traffic accident victims, but none of the 19 comparison subjects, met DSM-III-R criteria for PTSD at 1 year. Traffic accident victims who developed PTSD had higher levels of premorbid and comorbid psychopathology. Levels of posttraumatic symptoms were significantly higher from the outset in the subjects who developed PTSD and worsened progressively over the first 3 months, in contrast to subjects without PTSD, who manifested gradual amelioration of symptoms during this time. Existence of posttraumatic symptoms immediately after the accident was a better predictor of later PTSD than was accident or injury severity. CONCLUSIONS: In this study, a significant portion of injured traffic accident victims manifested PTSD 1 year after the event. The development of PTSD at 1 year can be predicted as early as 1 week after the accident on the basis of the existence and severity of early PTSD-related symptoms. However, the first 3 months following the accident appear to be the critical period for the development of PTSD.     

Acute Administration of Benzodiazepines as Part of Treatment Strategies for Epilepsy

Ad‐hoc administration of benzodiazepines (BZD) is well established in status epilepticus, but intermittent BZD use in the treatment of chronic epilepsy is little known beyond catamenial epilepsy. We aim to assess the use of acute drug administration (ADA) in the treatment of 24 patients with epilepsy (9 idiopathic generalized, 14 focal symptomatic/cryptogenic, 1 migraine‐epilepsy) receiving ADA for (1) prevention of generalized tonic‐clonic seizures (GTCS) after minor seizures, (2) prevention of seizures at perceived risk, (3) prevention of seizure clusters. Standard ADA was 10 mg oral clobazam (CLB); one patient received 10 mg rectal diazepam. Concomitant antiepileptic drugs (AED) remained unchanged whenever possible. Ten patients used ADA always correctly, 7 mostly, 7 sporadically or not. Outcome considering seizure control was positive in 44% of all patients (59% of those who actually used ADA): 5 patients seizure free, 1 free of disabling seizures, 4 with >50% reduction in seizure frequency. Eleven had minor or no improvement, 3 patients could not be rated. Thirteen (of 19 possible) patients attempted prevention of seizures or clusters, 10 with full or >50% success (52.6 resp. 76.9%). Prevention of clusters sometimes required higher or repetitive CLB dosing. Self rating of patients who did use ADA was positive or very positive in 88.2%. Retention rate was 66.7% of all patients, and 88.2% of those using ADA. The best results were obtained in idiopathic generalized epilepsy (IGE) patients with seizures habitually triggered by typical factors (sleep deprival, alcohol) but also some others were successful. The only adverse effect was gait ataxia in a multiple‐handicapped patient. ADA is an elegant and often successful but underused treatment option for selected patient groups where it can make the difference between becoming seizure free or not. Depending on the individual case it can be applied as monotherapy or in combination with a basis AED. A controlled investigation should follow.     

Arrêt des benzodiazépines chez des consommateurs chroniques : un essai en double insu du gluconate de lithium vs placebo

Benzodiazepines (BZD) dependence is frequent and induce withdrawal symptoms in high and low consumers, in both abrupt and taper discontinuations. Several withdrawal methods are described, involving either psychotherapy or pharmacotherapy. We have performed a multicenter, double-blind, randomised study comparing the efficacy and safety of lithium gluconate with that of a placebo in helping to achieve a complete and lasting BZD withdrawal. Outpatients receiving BZD since at least 6 months at a daily dose ranging from 10 to 40 mg diazepam or equivalent were eligible. Randomisation used a 3/2 design. This study consisted of four phases: a BZD stabilisation and randomly allocated placebo or lithium impregnation period of 4 weeks (D28 to D0) was followed by a 4-week BZD withdrawal period involving reduction of the initial dosage by 50% every week during 3 weeks (D0-D22) the third phase was an 8-week lithium maintenance phase (D28-D84) at the end of which the success of BZD withdrawal was assessed (primary aim). Finally, a 4-week lithium withdrawal phase D84-D112, where patients initially randomised to lithium were to randomly stop lithium either immediately or 2 weeks later, in order to assess a possible rebound effect due to lithium withdrawal. Lithium gluconate and placebo were dispensed in vials and were indistinguishable. Each verum vial contained 0.2796 mg lithium gluconate in 2 ml of isotonic glucose solution. Patients were to take three vials once a day. The main efficacy criterion was the rate of patients with a successful BZD withdrawal, defined as no BZD in urinalysis at D84 (or D98 for slow metabolisers) with no trial discontinuation due to anxiety, or due to withdrawal symptoms. Any other situation was considered as a failure. Secondary efficacy criteria included overall evaluation of treatment effect by both the investigator and the patient, and changes over time of COVI, HAMA and Physician's Withdrawal Checklist (PWC) mean scores. Efficacy parameters were compared between verum and placebo overall and according to the initial dosage of BZD. Safety was assessed on all patients who took at least one dose of the study treatment. Success rates in BZD withdrawal were analysed using the Fisher's exact test for the overall comparison and using the Cochran-Mantel-Haenszel (CMH) test for the comparison by initial BZD dosage. Changes over time in scores were analysed using non-parametric Wilcoxon-Mann-Whitney U tests for treatment effect comparison. Of 244 patients who entered the study, 146 were randomised to lithium gluconate and 98 to placebo. Eighty-six patients did not complete the study: 14 patients discontinued before the BZD withdrawal phase; 72 patients discontinued between BZD withdrawal and the end of the trial. The main reason for discontinuation was the recurrence of anxiety for 44 patients (22 in each group). Drop-out rates did not differ among treatment groups. All premature discontinuations were considered as failure. A total of 230 patients entered the BZD withdrawal phase and were taken into account for the ITT analyses, 136 patients allocated to lithium and 94 to placebo, of whom 32 presented a major protocol violation. Finally 198 patients were valid for the per-protocol analyses, 118 patients in the lithium group and 80 in the placebo one. There were no significant differences in demography and baseline characteristics among the two treatment groups. The overall success rates were high, over 60%, without significant difference between the two treatment groups. When considering the initial BZD daily dose, for patients taking 10 mg or less BZD, the success rates were still very high in both treatment groups without significant difference between them. There was too few patients doses over 20 mg/day to allow a relevant comparison. Nevertheless, for patients taking medium dosage, 11-20 mg/day, a difference of average 17.2% was observed between the two treatment groups in favour of the verum, without reaching statistical significance due to the size of this sub-group (lithium 61, placebo 38). The changes over time in anxiety scales (COVI, HAMA) and in withdrawal scales (Tyrer, PWC) did not allow to show any treatment effect, as expected with the observed low baseline scores. No effect of lithium withdrawal was reported. There was no rebound effect observed. The investigators assessed the safety of the products as ‘good’ or ‘very good’ for 95.7% of the patients allocated to lithium and 96.7% of those allocated to placebo. The success rates observed in the placebo group were unexpectedly high, over 60%, probably because of the intensive monitoring of the patients, leading to a difference between the two groups less important than expected and to an important lack of power of the trial. The main conclusion that can be drawn from this trial is the importance of a psychological help provided by the general practitioner. Nevertheless, the data suggested a positive effect of lithium gluconate in the BZD withdrawal, especially when taking into account the BZD initial dose: patients wishing to withdraw BZD and treated with BZD medium dosages seem to have better response when taking lithium in addition to the intensive monitoring, whereas in those treated with small BZD dosage are probably able to withdraw their treatment without drug therapy. There was not enough patients with high BZD initial dosage to draw any conclusion.     

Violence, alcohol, and completed suicide: a case-control study

OBJECTIVE: Violent behavior may represent a risk factor for suicide. The authors tested the hypothesis that violent behavior in the last year of life is associated with completed suicide, even after controlling for alcohol use disorders. METHOD: The authors analyzed data from the 1993 National Mortality Followback Survey, a nationally representative survey conducted by telephone interview with decedents' next of kin. Data on 753 victims of suicide were compared with data on 2,115 accident victims. Decedents ranged in age from 20 to 64. Dichotomous measures of violent behavior in the past year and history of alcohol misuse were derived by using the four-item CAGE questionnaire. Multiple logistic regression was used to evaluate the interactions of violent behavior with alcohol misuse, gender, and age, respectively, in predicting suicide versus accidental death. Education and race were included as covariates. RESULTS: Violent behavior in the last year of life was a significant predictor of suicide; the relationship was especially strong in individuals with no history of alcohol misuse, those who were younger, and women. CONCLUSIONS: Violent behavior distinguished suicide victims from accident victims, and this finding is not attributable to alcohol use disorders alone. Given that violent behavior increases the risk of suicide, violence prevention initiatives may serve to decrease the risk of suicide as well.     

Benzodiazepine abuse and dependence in psychiatric inpatients

Over a period of five and a half years, 792 inpatients with benzodiazepine (BZD) abuse and dependence in accordance with the WHO definition were registered at a university psychiatric hospital. One-quarter of them abused BZD exclusively, while three-quarters suffered from polytoxicomania or were alcohol dependent as well. It was possible to distinguish two groups of patients: one with primary, mainly low-dose, dependence preferring lorazepam and the other with secondary, often high-dose, dependence with diazepam as the main drug. In 108 patients with isolated BZD dependence, withdrawal symptoms of somatic, psychological, or perceptual quality were observed. The severity of the withdrawal syndrome seemed to depend on the time of consumption, dose, mode of withdrawal, and type of BZD compound. Following abrupt cessation, 11 patients with long-standing dependence on high BZD doses developed withdrawal psychoses, presenting a delirious, paranoid-hallucinatory, or depressive-anxious syndrome.     

The epidemiology of long-term benzodiazepine use

Recommendations for benzodiazepine (BZD) use suggest durations of no more than a few weeks, but studies report use for months, years, or even decades. This article examines the who (who are long-term users), why (why do they use BZD), what (what are patterns of long-term use) and how (how do they compare to all BZD users). The study population is from the National Population Health Survey in Canada which interviewed respondents four times at two-year intervals, asking about specific drugs use as well as demographic, lifestyle and health-related questions. Long-term BZD use was defined as BZD use for two successive cycles. Four percent of the Canadian population used BZD at any one time, half of whom also reported use in the previous cycle. Benzodiazepine users were more likely to be female, elderly, smokers, to prefer speaking a language other than English, to have insurance coverage for medication, and to have completed high school education. Almost none of these determinants predicted long-term use. Persons reporting BZD use in 2000 had an odds ratio (OR) of 38.6 for also using BZD in 1998, were more likely to use antidepressants (OR=8.5) and suffer from conditions such as poor health, stress, and pain. Most of these determinants had no association with long-term use or if they did at a considerably lower OR. Of the 395 BZD users in 2000, almost 48.4% also used BZD in the previous cycle and 17% in all three previous cycles. Benzodiazepine use in any previous cycle made BZD use in 2000 more likely, with use determined by how recent and the frequency of reported use, culminating in a very high OR of 83.3 for use in all three previous cycles. Continued use for any of the individual BZD tended to be largely for the same BZD. We conclude that: (1) the overriding determinant for BZD use was that of previous use; and (2) long-term use was not determined by the same factors as overall use, which is significant in developing approaches to dealing with long-term BZD use.     

The effectiveness of intravenous benzodiazepine for status epilepticus in Dravet syndrome

PurposeWe aimed to evaluate choice and efficacy of intravenous antiepileptic drugs (AEDs) for status epilepticus (SE) in Dravet syndrome and to find predictable clinical features demonstrating the effectiveness of benzodiazepine (BZD) for SE.MethodsWe retrospectively investigated the medical records in patients with Dravet syndrome and evaluated the effectiveness rate of intravenous AEDs and the rate of adverse effects. To find the clinical features of BZD-effective SE, we divided the SE episodes into the following two groups: BZD effective group and BZD non-effective group. The choice of treatment was dependent on physicians’ discretion according to the protocol for SE in our institution.ResultsSixty-eight SE episodes in 10 patients were assessed. The median age at SE was 31 months. Of 68 episodes, 42 episodes (61.8%) were in the BZD effective group and 26 (38.2%) in the BZD non-effective group. There were no significant differences in clinical features. In the BZD non-effective group, the effective rates of continuous midazolam, phenobarbital, phenytoin/fosphenytoin were 9/9 episodes (100%), 14/17 (82.4%), and 2/5 (40.0%), respectively. Adverse effects were identified in 19/68 episodes (27.9%), including 11/42 episodes in the BZD effective group and 8/26 in the BZD non-effective group, which was no statistical difference between the two groups. Respiratory suppression was found in all 19 episodes and the incidence of endotracheal intubation in the BZD non-effective group (15.4%) was higher than that in the BZD effective group (2.4%) (p = 0.046).ConclusionBZD may be used as first choice, and phenobarbital prior to continuous midazolam as second choice for SE with Dravet syndrome. There might be no predictable clinical features showing that BZD will be effective.     

Treatment of benzodiazepine withdrawal symptoms with carbamazepine

Summary In 18 patients with a benzodiazepine (BZD) dependency the drug was withdrawn. The dose of BZD was gradually reduced in nine of the patients, while the others were additionally treated with carbamazepine (CBZ) for a further 15 days after BZD discontinuation. Withdrawal symptoms were assessed every third day during the study period. When comparing results in both groups, a clear trend towards less severe withdrawal symptoms could be observed in the group treated with CBZ. Some of the differences were statistically significant on days 9–12 after BZD withdrawal. Fundamental withdrawal symptoms (like hypersensitivity to sensory stimuli, abnormal perception of movement, depersonalisation or derealisation) were also less severe in the group treated with CBZ compared with the group not receiving that treatment. These findings support the results of previous reports indicating a therapeutical effect of CBZ in BZD withdrawal.     

Acute and chronic posttraumatic stress disorder in motor vehicle accident victims

OBJECTIVE: This study reports the rates of acute and chronic posttraumatic stress disorder (PTSD) in a suburban community study group of 122 victims of serious motor vehicle accidents and a comparison group of 42 (who had been involved in minor, non-motor-vehicle accidents) followed over 12 months. METHOD: Motor vehicle accident victims were systematically recruited and examined with comparison subjects at 1, 3, 6, 9, and 12 months after the accident. The authors used the Structured Clinical Interview for DSM-III-R to assess DSM-III-R axis I disorders including PTSD. RESULTS: One month after the accident, 34.4% of the motor vehicle accident victims met criteria for PTSD (versus 2.4% of the comparison subjects). Similarly, at 3 and 6 months, rates of PTSD were higher (25.2% and 18.2%) in the motor vehicle accident victims than in the comparison group. Female victims were 4.64 times more likely than male victims to have PTSD at 1 month. Victims with a history of PTSD were 8.02 times more likely at 1 month and 6.81 times more likely at 3 months to have PTSD than those without a history of PTSD. Having an axis II disorder increased the risk for PTSD at 6 months. After adjustment for a history of PTSD and potentially confounding variables, women were 4.39 times more likely than men to develop PTSD at 1 month but did not have a higher risk for chronic PTSD; at 6 months, those with an axis II disorder were at greater risk of PTSD. CONCLUSIONS: Rates of PTSD are high in victims of serious motor vehicle accidents and remain high 9 months later. Female victims have an increased risk of acute but not chronic PTSD. Individuals with a history of PTSD are at risk of acute and chronic PTSD. An axis II disorder increases the risk for chronic but not acute PTSD.     

A programme for short-term withdrawal from benzodiazepines in geriatric hospital inpatients: success rate and effect on subjective sleep quality.

OBJECTIVE: We tested the hypothesis that a short-term programme for withdrawal of benzodiazepines (BZD) is feasible in hospitalized geriatric patients.METHODS: Fifty-six geriatric subjects who had been taking BZD for at least 3 months were asked to discontinue these drugs upon admission to the inpatient ward. A withdrawal programme including initial substitution therapy combined with psychological consulting was offered. The usual BZD medication was replaced by either lormetazepam 1 mg or trazodone 50 mg, administered at bedtime. After 1 week of replacement therapy all sedative medication was stopped. The subjective estimations of sleep quality were evaluated four times during a period of 6 weeks. RESULTS: Forty-nine patients agreed to participate. In this group four subjects (8.2%) resumed BZD use while in the hospital and another seven subjects (14.3%) relapsed after discharge. Therefore, the overall success rate was 77.6% in the group of volunteers and 67. 9% in the total group of eligible patients. The data of the present study further demonstrate that no major withdrawal symptoms occurred and that the subjective quality of sleep remained virtually unchanged in the course of the programme. The sleep quality was not significantly different in patients on trazodone versus patients on lormetazepam. The success rate was similar in both drug substitution groups.CONCLUSIONS: Short-term withdrawal of BZD may be achieved in two-thirds of elderly hospital inpatients without deterioration of sleep quality or other deleterious side-effects.     

Conduites addictives, psychotraumatisme et accidents de la route

Eight to 40% of subjects confronted with a motor vehicle accident present with a posttraumatic stress disorder (PTSD). Besides its professional, functional social, environmental impact, PTSD increase the risk comorbide substance use disorder. We present a prospective epidemiological long-term study of a population of 273 patients victims of a motor vehicle accident hospitalized in Trauma & Orthopedic Department with 6 months follow-up. We find a Post-Traumatic Stress Disorder (PTSD) rate in accordance with literature: 20.8% (6 weeks after accident) and 16.6% (6 months after the accident) for the whole population. We did not note increase of substance abuse disorder (alcohol or opiates) (6 weeks or 6 months after the accident) for the whole population (or even a reduction). But we found a more important proportion of PTSD in patients initially presenting with substance abuse disorder at 6 weeks and at 6 months. On the other hand, we found an increase of substance misuse in patients presenting with a PTSD (at 6 weeks and 6 months) in comparison with of general population. We discuss how initial substance abuse disorder could impact on psychopathological disorders onset afterwards and the importance of early screening as part of the secondary prevention for PTSD using itinerant unit of addictology and/or psychiatry (i.e. Consultation Liaison Addictology and Psychiatry).     

Status Epilepticus Related to Alcohol Abuse

We reviewed the case records of 249 adult patients with generalized convulsive status epilepticus (SE) examined at San Francisco General Hospital between 1977 and 1989 and identified 27 patients (10.8%) in whom alcohol abuse was the only identifiable precipitating cause of SE. In 12 patients (44% of the study group), SE was the first presentation of alcohol-related seizures. Seizures with focal features were observed in 11 patients (40.1%), but there was little correlation with localized computed tomography (CT) or EEG abnormalities. SE was controlled with phenytoin (PHT), with or without a benzodiazepine (BZD), in 18 patients (66.7%). Twentytwo patients (81.5%) were discharged with no new neurologic deficits, but time to recovery of baseline mental status was prolonged (>12 h) in 24 patients. With regard to alcohol abuse history, study patients did not differ from a comparison group with isolated alcohol withdrawal seizures. The results indicate that alcohol abuse is a common cause of SE and that SE may be the first presentation of alcohol-related seizures. Furthermore, the outcome of patients with alcohol-related SE compares favorably with that of patients with SE due to other causes, but recovery of these patients may be complicated by a prolonged postictal state.